Who
Bernard Coulie
Director
Company insider
Files Form 4 as: Director, Septerna; President and CEO, Pliant Therapeutics; Director, SQZ Biotechnologies Co.
In numbers
- Trades disclosed
- 145
- Buys
- 0
- Sells
- 31
- Bought
- $0
- Sold
- $13.7M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 31 Mar 2020
- Last trade
- 26 Jun 2026
- Last filed
- 30 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Jun 2026filed 30 Jun 2026 | SEPN Septernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | SEPN Septernaoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —146,841 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —206,300 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —256,300 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —256,300 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —325,000 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —325,000 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —146,841 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —327,262 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —146,841 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —146,841 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —327,262 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —327,262 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —250,000 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —440,000 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —440,000 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —206,300 at $0.00 | filing |
| 17 Apr 2026filed 17 Apr 2026 | PLRX Pliant Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —206,300 at $0.00 | filing |
News
Pliant Therapeutics Appoints Craig Blanchette, Ph.D., as Senior Vice President, Research (siRNA)PLRX · manilatimes.net · 20 Oct 2026
0 headlines in the last 90 days name Bernard Coulie; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.